Search

Restrictions

EHA is guided by the concept of supporting as many young investigators/clinicians as possible in their career development. Therefore, double awarding is not allowed.

Impactful activitiesGuideline development projectThe most relevant and impactful activities of the SWG include those related to the guideline development project. There were regular meetings with the Guidelines Expert Panel Committee.

Expert opinions for specific non-malignant hematologic diseases

Red Cells and Iron
Hemoglobinopathies: Sickle Cell Disease and Thalassemia

Sickle Cell Disease Association of America (SCDSS)
Sickle Cell Disease and COVID-19: An Outline to Decrease Burden and Minimize Morbidity
Italian Society of Thalassemia and Hemoglobinopathies

Thalassemia and Hemoglobin disorders Italian Society
Thalassemia International Federation (TIF)
The COVID-19…

COVID-19 Expert opinions

Expert opinions for hematologists in COVID-19 crisis
COVID-19, caused by SARS-CoV-2, is expected to be a devastating infection in many patients with hematologic diseases.

Highlights from the SWG

EventsParticipation in the 19th European LeukemiaNet (ELN) SymposiumLocation and dateThis event was held in Mannheim, Germany, on April 18, 2023. Chairs
D. Hoelzer
S. Chiaretti
Topics
Blinatumomab Frontline HOVON Trial (A. Rijneveld, Netherlands). Inotuzumab ozogamicin in MRD+ ALL (G.

Fellowships & Grants Committee

Current committee members
Dominique Bonnet, United Kingdom (Chair (EHA Board))
David Kent, United Kingdom (Vice-Chair (non-Board))
Regular members
Renée Beekman, Spain
Olivier Bernard, France
Niccolò Bolli, Italy
Tom Cupedo, The Netherlands
Michaela Fontenay, France
Julia Hauer, Germany
Antonis Kattamis, Greece
Elisa Laurenti, United Kingdom
Dimitrios Mougiakakos, Germany
César Nombela-Arrieta, Switzerland
Rebekka Schneider-Kramann, The Netherlands
Jürg…

IVDR

As of May 26, 2022, the new EU In Vitro Diagnostic medical devices Regulation (IVDR) comes into effect.